India · Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 310.43 billion. The enterprise value is 303.49 billion.
| Market Cap | 310.43B |
| Enterprise Value | 303.49B |
Important Dates
The last earnings date was Monday, November 3, 2025.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | Nov 10, 2025 |
Share Statistics
Ajanta Pharma has 124.89 million shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | 124.89M |
| Shares Outstanding | 124.89M |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 42.34% |
| Owned by Institutions (%) | 20.34% |
| Float | 41.84M |
Valuation Ratios
The trailing PE ratio is 31.90 and the forward PE ratio is 27.56. Ajanta Pharma's PEG ratio is 2.00.
| PE Ratio | 31.90 |
| Forward PE | 27.56 |
| PS Ratio | 6.24 |
| PB Ratio | 7.19 |
| P/TBV Ratio | 7.26 |
| P/FCF Ratio | 96.09 |
| P/OCF Ratio | 46.70 |
| PEG Ratio | 2.00 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.47, with an EV/FCF ratio of 93.94.
| EV / Earnings | 31.17 |
| EV / Sales | 6.10 |
| EV / EBITDA | 22.47 |
| EV / EBIT | 25.32 |
| EV / FCF | 93.94 |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.93 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.76 |
| Interest Coverage | 52.97 |
Financial Efficiency
Return on equity (ROE) is 24.37% and return on invested capital (ROIC) is 18.12%.
| Return on Equity (ROE) | 24.37% |
| Return on Assets (ROA) | 14.32% |
| Return on Invested Capital (ROIC) | 18.12% |
| Return on Capital Employed (ROCE) | 26.56% |
| Revenue Per Employee | 5.17M |
| Profits Per Employee | 1.01M |
| Employee Count | 9,628 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, Ajanta Pharma has paid 2.75 billion in taxes.
| Income Tax | 2.75B |
| Effective Tax Rate | 22.03% |
Stock Price Statistics
The stock price has decreased by -15.28% in the last 52 weeks. The beta is 0.21, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -15.28% |
| 50-Day Moving Average | 2,486.71 |
| 200-Day Moving Average | 2,588.27 |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 101,293 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 49.73 billion and earned 9.74 billion in profits. Earnings per share was 77.93.
| Revenue | 49.73B |
| Gross Profit | 37.67B |
| Operating Income | 11.99B |
| Pretax Income | 12.49B |
| Net Income | 9.74B |
| EBITDA | 13.38B |
| EBIT | 11.99B |
| Earnings Per Share (EPS) | 77.93 |
Balance Sheet
The company has 9.40 billion in cash and 2.46 billion in debt, giving a net cash position of 6.94 billion or 55.59 per share.
| Cash & Cash Equivalents | 9.40B |
| Total Debt | 2.46B |
| Net Cash | 6.94B |
| Net Cash Per Share | 55.59 |
| Equity (Book Value) | 43.15B |
| Book Value Per Share | 345.45 |
| Working Capital | 22.34B |
Cash Flow
In the last 12 months, operating cash flow was 6.65 billion and capital expenditures -3.42 billion, giving a free cash flow of 3.23 billion.
| Operating Cash Flow | 6.65B |
| Capital Expenditures | -3.42B |
| Free Cash Flow | 3.23B |
| FCF Per Share | 25.87 |
Margins
Gross margin is 75.75%, with operating and profit margins of 24.10% and 19.58%.
| Gross Margin | 75.75% |
| Operating Margin | 24.10% |
| Pretax Margin | 25.11% |
| Profit Margin | 19.58% |
| EBITDA Margin | 26.91% |
| EBIT Margin | 24.10% |
| FCF Margin | 6.50% |
Dividends & Yields
This stock pays an annual dividend of 28.00, which amounts to a dividend yield of 1.12%.
| Dividend Per Share | 28.00 |
| Dividend Yield | 1.12% |
| Dividend Growth (YoY) | -48.15% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 35.93% |
| Buyback Yield | 0.61% |
| Shareholder Yield | 1.72% |
| Earnings Yield | 3.14% |
| FCF Yield | 1.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |